Condition: Breast Cancer Invasive · Early-stage Breast Cancer · High Risk Breast Carcinoma · Sponsor: University of Illinois at Chicago
To determine the effect of low dose azacitidine therapy on tumor infiltrating lymphocytes (TILs) in primary tumors from patients with high-risk early stage breast cancer, paired t-tests will be first used to compare TIL count in pre- and post-treatment specimens.
This description comes directly from the study's public registry record.
VK Gadi, MD, PhD · 312-996-1581 · vkgadi@uic.edu
Michelle Karan, BS · 224-563-7137 · makaran2@uic.edu
Always discuss trial participation with your own doctor first.
| University of Illinois Cancer Center | Chicago, Illinois, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04891068